AU3623700A - Apoptosis inducing molecule ii and methods of use - Google Patents
Apoptosis inducing molecule ii and methods of useInfo
- Publication number
- AU3623700A AU3623700A AU36237/00A AU3623700A AU3623700A AU 3623700 A AU3623700 A AU 3623700A AU 36237/00 A AU36237/00 A AU 36237/00A AU 3623700 A AU3623700 A AU 3623700A AU 3623700 A AU3623700 A AU 3623700A
- Authority
- AU
- Australia
- Prior art keywords
- methods
- apoptosis inducing
- inducing molecule
- molecule
- apoptosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4747—Apoptosis related proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Communicable Diseases (AREA)
- Cell Biology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12404199P | 1999-03-11 | 1999-03-11 | |
US60124041 | 1999-03-11 | ||
US13745799P | 1999-06-04 | 1999-06-04 | |
US60137457 | 1999-06-04 | ||
US14265799P | 1999-07-06 | 1999-07-06 | |
US60142657 | 1999-07-06 | ||
US14832699P | 1999-08-11 | 1999-08-11 | |
US60148326 | 1999-08-11 | ||
US16838099P | 1999-12-02 | 1999-12-02 | |
US60168380 | 1999-12-02 | ||
PCT/US2000/006332 WO2000053223A1 (en) | 1999-03-11 | 2000-03-10 | Apoptosis inducing molecule ii and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
AU3623700A true AU3623700A (en) | 2000-09-28 |
Family
ID=27537685
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU36237/00A Abandoned AU3623700A (en) | 1999-03-11 | 2000-03-10 | Apoptosis inducing molecule ii and methods of use |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1161261A1 (en) |
JP (1) | JP2003528030A (en) |
AU (1) | AU3623700A (en) |
CA (1) | CA2367315A1 (en) |
WO (1) | WO2000053223A1 (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7285267B2 (en) | 1997-01-14 | 2007-10-23 | Human Genome Sciences, Inc. | Tumor necrosis factor receptors 6α & 6β |
CN1247567A (en) | 1997-01-14 | 2000-03-15 | 人体基因组科学有限公司 | Tumor necrosis factor receptor alfa 6 and receptor beta 6 |
US7118742B2 (en) | 1997-07-07 | 2006-10-10 | La Jolla Institute For Allergy And Immunology | Ligand for herpes simplex virus entry mediator and methods of use |
US6998108B1 (en) | 1997-07-07 | 2006-02-14 | La Jolla Institute For Allergy And Immunology | Antibodies to p30 polypeptides and methods making and using same |
WO2001079496A2 (en) * | 2000-03-13 | 2001-10-25 | La Jolla Institute For Allergy And Immunology | Ligand for herpes simplex virus entry mediator and methods of use |
ATE365214T1 (en) * | 2000-04-12 | 2007-07-15 | Jolla Inst Allergy Immunolog | HERPES SIMPLEX CELL ENTRY-MEDIATING PROTEIN LIGAND AND METHODS OF USES THEREOF |
EP1364653A4 (en) * | 2001-02-23 | 2005-01-26 | Takeda Pharmaceutical | Casoase 3 inhibitors |
WO2002066049A1 (en) * | 2001-02-23 | 2002-08-29 | Takeda Chemical Industries, Ltd. | Agents for plasmic change |
US20020141970A1 (en) * | 2001-03-05 | 2002-10-03 | Pettit Dean K. | Stable aqueous solutions of granulocyte macrophage colony-stimulating factor |
WO2003089575A2 (en) * | 2002-04-15 | 2003-10-30 | Human Genome Sciences, Inc. | Antibodies that specifically bind to tl5 |
US7811983B2 (en) * | 2003-06-11 | 2010-10-12 | The University Of Chicago | Increased T-cell tumor infiltration and eradication of metastases by mutant light |
US20080233132A1 (en) * | 2006-11-03 | 2008-09-25 | Miller Stephen D | Multiple sclerosis therapy |
EP3750918A1 (en) | 2015-01-20 | 2020-12-16 | IGM Biosciences, Inc. | Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof |
WO2023155872A1 (en) * | 2022-02-18 | 2023-08-24 | 江苏众红生物工程创药研究院有限公司 | Method for realizing controlled release and sustained release of activity of bioactive molecules and use for drugs |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0904278A4 (en) * | 1996-03-22 | 1999-09-15 | Human Genome Sciences Inc | Apoptosis inducing molecule ii |
EP0922099B1 (en) * | 1996-07-19 | 2004-09-08 | Takeda Chemical Industries, Ltd. | Fas ligand-like protein, its production and use |
US6346388B1 (en) * | 1997-08-13 | 2002-02-12 | Smithkline Beecham Corporation | Method of identifying agonist and antagonists for tumor necrosis related receptors TR1 and TR2 |
AU9222698A (en) * | 1997-09-05 | 1999-03-22 | Millennium Biotherapeutics, Inc. | Novel molecules of the tnfr-ligand-related protein family and uses thereof |
EP1054968A1 (en) * | 1998-02-20 | 2000-11-29 | Human Genome Sciences, Inc. | Apoptosis inducing molecule ii and methods of use |
-
2000
- 2000-03-10 AU AU36237/00A patent/AU3623700A/en not_active Abandoned
- 2000-03-10 JP JP2000603712A patent/JP2003528030A/en not_active Withdrawn
- 2000-03-10 WO PCT/US2000/006332 patent/WO2000053223A1/en not_active Application Discontinuation
- 2000-03-10 CA CA002367315A patent/CA2367315A1/en not_active Abandoned
- 2000-03-10 EP EP00914913A patent/EP1161261A1/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
CA2367315A1 (en) | 2000-09-14 |
WO2000053223A1 (en) | 2000-09-14 |
JP2003528030A (en) | 2003-09-24 |
EP1161261A1 (en) | 2001-12-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU4520801A (en) | Novel substituted phenanthridinones and methods of use thereof | |
AU3867400A (en) | Methods of using bioelastomers | |
AU5013100A (en) | Maize rs81 promoter and methods of use thereof | |
HUP0202477A3 (en) | Use of phthalazine derivatives | |
AU2002314466A1 (en) | Withasol and methods of use | |
AU2002225954A1 (en) | Dipeptidylpeptidases and methods of use | |
AU6340600A (en) | Telomerase inhibitors and methods of their use | |
AU715620C (en) | Therapeutic methods and uses | |
AU3622600A (en) | Metalloproteinases and methods of use therefor | |
AU8967998A (en) | Antibiotic-ligand conjugates and methods of use thereof | |
AU3623700A (en) | Apoptosis inducing molecule ii and methods of use | |
AU2972199A (en) | Apoptosis inducing molecule ii and methods of use | |
MXPA02000779A (en) | Highly purified cytokine activating factor and methods of use. | |
AU3501700A (en) | Human endokine alpha and methods of use | |
AU2529799A (en) | Benzofuran-4-carboxamides and their therapeutic use | |
AU2669201A (en) | Taccalonolides and their use | |
PL350963A1 (en) | Use of arylalkanoylpyridazines | |
AU4021700A (en) | Methods of use of beta1-integrin inhibitors | |
AU5974100A (en) | 6-carboxyphenyldihydropyridazinone derivatives and use thereof | |
AU3078101A (en) | Micromolds fabricated using mems technology and methods of use therefor | |
AU6084598A (en) | Antibiotic-ligand conjugates and methods of use thereof | |
AU6150400A (en) | Tetrahydroquinolinyl-6-methyldihydrothiadiazinone derivatives and use thereof | |
AU2567599A (en) | Anti-ccr1 antibodies and methods of use therefor | |
AU2001261785A1 (en) | Vdup1 promoter and methods of use thereof | |
AU2279601A (en) | Npr1-interactors and methods of use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |